Skip to content

Trimodal Prehabilitation in Pancreatic Cancer Patients Urdergoing Neoadjuvant Treatment

Trimodal Prehabilitation in Pancreatic Cancer Patients Candidate to Neoadjuvant Treatment: A Pilot Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05722223
Acronym
PREPANC
Enrollment
14
Registered
2023-02-10
Start date
2022-03-15
Completion date
2025-05-09
Last updated
2025-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neoplasms

Keywords

exercise, pancreatic, cancer, trimodal

Brief summary

Pancreatic cancer is a disease with a very poor prognosis and less than 10% of these patients live beyond 5 years from diagnosis. Further, it is expected to become the second leading cause of death in the coming years. Today, surgery remains the cornerstone in curing this disease, but the addition of chemotherapy is needed to improve survival. The impact of adjuvant treatment has been previously demonstrated and its efficacy is absolute. However, neoadjuvant chemotherapy (pre-surgery) improves the results after surgery (achieving earlier stages and with better prognosis) and would lead to better survival results. Besides, the moment of cancer diagnosis is a moment of special receptivity to change lifestyles (teachable moment). Multimodal prehabilitation includes 1) physical exercise; 2) nutritional and 3) psychological support. The potential advantages of prehabilitation during neoadjuvant therapy would be 1) the possibility of achieving a better physical condition to face surgery; 2) fewer postoperative complications; 3) more likely to receive adjuvant treatment after surgery; 4) better physical function at the end of treatments. To date, most studies have focused on lung and prostate cancer, with a high prevalence of men in the series. This strategy has previously been explored, showing that it is safe and feasible, (Loughney et al). We have not identified any study of trimodal prehabilitation during neoadjuvant treatment and none that has integrated motivational strategies to maintain adherence. Patients during chemotherapy have perceived several adverse effects that could limit adherence to the program. In this regard, a review on the motivation and exercise in cancer survivors shows that it is necessary to apply theoretical frameworks to understand cognitive and motivational processes and develop educational interventions. The self-determination theory is one of the motivational theories most applied today to the analysis of factors related to the adoption of healthy lifestyles. Likewise, patients who are motivated are more likely to improve healthy habits and obtain greater adherence to exercise performance. Therefore, we aimed of carrying out an intervention (pilot study) in ten patients to describe the feasibility of a trimodal prehabilitation program in the hospital environment, applying motivational strategies and a mixed-method (face-to-face and online).

Detailed description

outcome measures refer to feasibility of the intervention: Recruitment Attendance to the training sessions Attendance to psychologist and nutritionist sessions And also to physical condition Cardiorespiratory fitness Muscular strength Body composition Physical activity Quality of life Fatigue score

Interventions

COMBINATION_PRODUCTTrimodal prehabilitation

Pancreatic cancer patients (not stage 4) will undergo trimodal prehabilitation: nutrition, psychological, and exercise support.

Sponsors

Puerta de Hierro University Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

All the participants will receive trimodal prehabilitation. Only one arm

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* More than 18 years old * ECOG 0-2 * Being able to complete the mile-time test * Stages I-III * Being able to understand the informed consent * Pancreatic cancer diagnosed

Exclusion criteria

* Metastasic cancer

Design outcomes

Primary

MeasureTime frameDescription
To explore the feasibility of a trimodal prehabilitation program in the hospital setting1 yearAdherence to 70% of supervised physical exercise sessions and to nutrition and psychologist sessions

Secondary

MeasureTime frameDescription
Changes in (estimated) cardiorespiratory fitness3-6 months (from 1st treatment to surgery)Mile-time test
Changes in muscle strength3-6 months (from 1st treatment to surgery)Handgrip by dynamometry
Changes in body mass index3-6 months (from 1st treatment to surgery)BMI (Body Mass Index kg/sm)
Changes in body composition3-6 months (from 1st treatment to surgery)waist, hip, calf circumferences
Changes in levels of physical activity at week3-6 months (from 1st treatment to surgery)Accelerometry
Changes in quality of life3-6 months (from before1st treatment to surgery)EORTC-QLQ-C30 (European Organization for Research and Treatment of Cancer. Quality of Life questionnaire. C30. all scores of the QLQ-C30 were transformed linearly so that all scales ranged from 0 to 100. In the function scales higher scores represent a better level of functioning while in the case of symptom scales/items higher scores mark a higher level of symptomatology or problems.
Describe changes in fatigue levels3-6 months (from before 1st treatment to surgery)PERFORM (Multidimensional scale 12-60. The higher the less fatigue)
Describe post-surgical complicationsthree monthsSurgical wound and pancreatic fistula
Nutritional status3-6 months (from 1st treatment to surgery)body mass index
Percentage of pathological complete responses4-6 weeks after surgeryPercentage of patients with no viable cells in the surgical specimen
Percentage of patients receiving adjuvant therapyThree months after surgeryPatients that received at least two cycles after surgery
Hindrances and facilitators of patientsDuring the prehabilitation program (3-6 months for each patient)Qualitative methods. semi-structured interviews and observation
Anxiety and depression3-6 months (from 1st treatment to surgery)Hospital Anxiety and Depression Scale questionnaire. Values 8-21. The higher the worse
Dose intensity in neoadjuvant treatment3-6 months (from 1st treatment to surgery)percentage of intended doses that are administered in the due time

Other

MeasureTime frameDescription
Circulating tumor DNA and mutational variationsbefore initiating chemotherapycirculant tumor DNA

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026